Disciplined Growth Investors Inc. MN lifted its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 2.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 714,361 shares of the medical equipment provider’s stock after purchasing an additional 20,311 shares during the quarter. Disciplined Growth Investors Inc. MN owned approximately 0.64% of MiMedx Group worth $9,008,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. BlueCrest Capital Management Ltd acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $126,000. PVG Asset Management Corp acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $127,000. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of MiMedx Group by 6,262.5% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,725 shares of the medical equipment provider’s stock worth $151,000 after purchasing an additional 12,525 shares in the last quarter. First Republic Investment Management Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $153,000. Finally, ClariVest Asset Management LLC grew its holdings in shares of MiMedx Group by 81.1% during the 3rd quarter. ClariVest Asset Management LLC now owns 12,953 shares of the medical equipment provider’s stock worth $154,000 after purchasing an additional 5,800 shares in the last quarter. 80.35% of the stock is currently owned by institutional investors.
MDXG stock opened at $7.27 on Wednesday. The company has a market capitalization of $817.22, a P/E ratio of 23.45, a P/E/G ratio of 0.96 and a beta of 1.65. MiMedx Group, Inc. has a 52-week low of $6.05 and a 52-week high of $18.25.
MiMedx Group declared that its board has approved a stock buyback program on Wednesday, December 13th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical equipment provider to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.
Several analysts have recently weighed in on MDXG shares. Zacks Investment Research lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Friday, December 8th. BidaskClub lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Piper Jaffray Companies reissued a “buy” rating and set a $18.00 price objective on shares of MiMedx Group in a report on Friday, December 1st. Needham & Company LLC lowered MiMedx Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 20th. Finally, Craig Hallum reissued a “buy” rating on shares of MiMedx Group in a report on Tuesday, February 27th. Four analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. MiMedx Group currently has a consensus rating of “Hold” and a consensus target price of $14.75.
MiMedx Group Company Profile
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.